^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

1370P - PD-L1 expression as a predictive biomarker for chemotherapy response in metastatic non-small cell lung cancer (mNSCLC)

Published date:
09/14/2020
Excerpt:
Twelve trials were identified, involving 4031 patients with EGFR/ALK wild type tumors…Chemotherapy consisted of a cisplatin/carboplatin backbone with pemetrexed/gemcitabine/nab-paclitaxel...High PD-L1 expression is associated with improved ORR with platinum doublet chemotherapy in mNSCLC.